NCT04288778 - A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions

Diabetes Mellitus

Interventions

DRUG

Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)

Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.

Trial Locations (10)

160012

Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh

160062

Fortis Hospital, Mohali

395002

Nirmal Hospital Pvt. Ltd., Surat

411001

Jehangir Clinical Development Center Pvt Ltd, Pune

411021

Chellaram Diabetes Institute, Pune

500024

Thumbay Hospital New life / Endocrinology, Hyderabad

560092

Lifecare Hospital and Research Centre, Bengaluru

695032

Jothydev's Diabetes Research Centre, Trivandrum

781033

Excelcare Hospitals (A unit of Asclepius Hospitals and Health Care Pvt. Ltd.), Guwahati

641 009

Kovai Diabetes Specialty Centre & Hospital, Coimbatore